Search

Home > New FDA Approvals > 137 - Tafinlar + Mekinist for BRAF V600-mutant melanoma; elamipretide for treatment of Leber's hereditary optic neuropathy; macitentan for CTEPH
Podcast: New FDA Approvals
Episode:

137 - Tafinlar + Mekinist for BRAF V600-mutant melanoma; elamipretide for treatment of Leber's hereditary optic neuropathy; macitentan for CTEPH
Category: Science & Medicine
Duration: 00:10:21
Publish Date: 2018-05-01 06:00:00
Description:

May 1, 2018 

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com

1:22 Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma https://www.prnewswire.com/news-releases/novartis-receives-fda-approval-of-tafinlar--mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma-300639403.html

4:27 Stealth BioTherapeutics granted orphan drug designation of elamipretide for treatment of Leber's hereditary optic neuropathy https://www.prnewswire.com/news-releases/stealth-biotherapeutics-granted-orphan-drug-designation-of-elamipretide-for-treatment-of-lebers-hereditary-optic-neuropathy-300638085.html

6:22 Actelion submits supplemental new drug application to US FDA seeking approval of OPSUMIT® (macitentan) for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) https://www.prnewswire.com/news-releases/actelion-submits-supplemental-new-drug-application-to-us-fda-seeking-approval-of-opsumit-macitentan-for-the-treatment-of-chronic-thromboembolic-pulmonary-hypertension-cteph-300638648.html

Brought to you by Nascent Medical. For assistance with medical writing, please email info@nascentmc.com.

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
Total Play: 0